A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.
Eligibility criteria
Qualifiers
Documented histologically or cytologically confirmed, advanced, unresectable/metastatic solid tumor measurable by RECIST v1.1.
Disqualifiers
History of anaphylactic reactions to irinotecan and/or bevacizumab.
Previously received therapy targeting CEACAM5.
Grade ≥3 ILD/pneumonitis.
Other protocol-defined Inclusion/Exclusion criteria apply.
Trial design
Treatments tested in this trial
- BMS-986490
- Bevacizumab
Treatment groups
360 Participants
are divided into 5 treatment groupsLocations
6Australia
Tasman Oncology Research4215, SouthportQueensland, Australia
Canada
Princess Margaret Cancer CentreM5G 2M9, TorontoOntario, Canada
United States
Local Institution - 000790033, Los AngelesCalifornia, United States
Local Institution - 001749546, Grand RapidsMichigan, United States
Sponsors and collaborators
Bristol-Myers Squibb
Lead sponsor
Source ClinicalTrials.gov